Literature DB >> 28968363

Guillain-Barré Syndrome.

Peter D Donofrio.   

Abstract

PURPOSE OF REVIEW: This article reviews the current state of Guillain-Barré syndrome (GBS), including its clinical presentation, evaluation, pathophysiology, and treatment. RECENT
FINDINGS: GBS is an acute/subacute-onset polyradiculoneuropathy typically presenting with sensory symptoms and weakness over several days, often leading to quadriparesis. Approximately 70% of patients report a recent preceding upper or lower respiratory tract infection or gastrointestinal illness. Approximately 30% of patients require intubation and ventilation because of respiratory failure. Nerve conduction studies in the acute inflammatory demyelinating polyradiculoneuropathy (AIDP) form of GBS typically show evidence for a multifocal demyelinating process, including conduction block or temporal dispersion in motor nerves. Sural sparing is a common phenomenon when testing sensory nerves. CSF analysis commonly shows an elevated protein, but this elevation may not be present until the third week of the illness. Patients with AIDP are treated with best medical management and either IV immunoglobulin (IVIg) or plasma exchange.
SUMMARY: GBS is a common form of acute quadriparesis; a high level of suspicion is needed for early diagnosis. With appropriate therapy, most patients make a very good to complete recovery.

Entities:  

Mesh:

Year:  2017        PMID: 28968363     DOI: 10.1212/CON.0000000000000513

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  21 in total

1.  Guillain-Barré Syndrome During the Postpartum Period.

Authors:  Mohammed Aabdi; Yassine Mellagui; Amine Bensaid; Houssam Bkiyar; Brahim Housni
Journal:  Cureus       Date:  2020-12-10

2.  Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report.

Authors:  Jialing Li; Danghan Xu; Yingyu Liu; Yang Cao; Jun He; Muxi Liao
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

3.  Are Repeated Cycles of Intravenous Immunoglobulin Justified in Patients With Poorly Responsive Guillain-Barré Syndrome?

Authors:  Hussein Algahtani; Bader Shirah; Khalid Alrefaei; Mohammed Albassam; Nawal Abdelghaffar
Journal:  Neurohospitalist       Date:  2019-12-13

4.  Intravenous immunoglobulin in COVID-19 associated Guillain-Barré syndrome in pregnancy.

Authors:  Jao Jarro Garcia; Christian Wilson Turalde; Marjorie Anne Bagnas; Veeda Michelle Anlacan
Journal:  BMJ Case Rep       Date:  2021-05-11

5.  Guillain-Barre Syndrome Following a Snakebite: A Case Report and Review of Literature.

Authors:  Sajid Hameed; Mubashar Memon; Sara Khan
Journal:  Cureus       Date:  2019-07-30

Review 6.  Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature.

Authors:  Hang Liu; Ying Ma
Journal:  Brain Behav       Date:  2019-12-11       Impact factor: 2.708

7.  Guillain-Barré syndrome complicated by takotsubo cardiomyopathy: an under-recognised association.

Authors:  Timothy Jones; Neelan Umaskanth; James De Boisanger; Henry Penn
Journal:  BMJ Case Rep       Date:  2020-02-13

8.  Acute motor-sensory axonal polyneuropathy variant of Guillain-Barre syndrome complicating the recovery phase of coronavirus disease 2019 infection: a case report.

Authors:  Ahmed Maseh Haidary; Sarah Noor; Esmatullah Hamed; Tawab Baryali; Soma Rahmani; Maryam Ahmad; Farahnaz Erfani; Hashmatullah Azimi; Habib Ul Rahman Habib; Gul Ahmad Tahiri; Ramin Saadaat; Abdul Sami Ibrahimkhil; Esmatullah Esmat; Haider Ali Malakzai
Journal:  J Med Case Rep       Date:  2021-07-16

9.  Guillain Barre Syndrome: A Single Center Experience.

Authors:  Onur Akan; Canan Emir; Cihat Örken; Serap Üçler
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2020-03-25

10.  A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.

Authors:  Nicola Alessandro Nasuelli; Fabiola De Marchi; Michela Cecchin; Irene De Paoli; Susanna Onorato; Roberto Pettinaroli; Giovanni Savoini; Laura Godi
Journal:  Neurol Sci       Date:  2021-07-17       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.